Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833260 | 1.00 | MEN1 (0.33) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL919128 | 1.00 | MEN1 (0.33) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL3936793 | 0.90 | MEN1 (0.35) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL1035235 | 0.90 | MEN1 (0.35) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL13739930 | 0.90 | MEN1 (0.35) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL28268357 | 0.89 | MEN1 (0.38) | MEN1MAPK1KMT2AGAABTK | |
| Hydrochloric Acid SCHEMBL20137871 | 0.89 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| Hydrochloric Acid SCHEMBL29182805 | 0.89 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| Hydrochloric Acid SCHEMBL20137760 | 0.89 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL24690393 | 0.88 | RORC (0.35) | MEN1MAPK1KMT2ARORCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4631942-A1 | PAN-KRAS DEGRADING AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2025108225-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVE AS PARG INHIBITOR | 上海复星医药（集团）股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
| EP-0723545-B1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LAB (US) | 2002-05-08 | — | — | EP | disclosed |
| CN-1053188-C | Quinolizinone type compounds | ABBOTT LAB (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| CN-1137273-A | Quinolizinone type compounds | ABBOTT LAB (US) | 1996-12-04 | — | — | CN | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | MEN1 1196/4885MAPK1 2918/4885KMT2A 208/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | MEN1 1196/4885MAPK1 2918/4885KMT2A 208/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | MEN1 4405/4885MAPK1 3157/4885KMT2A 3837/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | MEN1 4405/4885MAPK1 3157/4885KMT2A 3837/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | MEN1 1196/4885MAPK1 2918/4885KMT2A 208/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | MEN1 4216/4885MAPK1 2873/4885KMT2A 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.